The development of a double-antibody radioimmunoassay for detecting ovarian tumor-associated antigen fraction OCA in plasma.
Ovarian tumor-associated antigen isolated from human tumor tissue was shown to have a different mobility from that of carcinoembryonic antigen (CEA) in both acrylamide gel electrophoresis and immunoelectrophoresis in agarose. The ovarian tumor antigen is composed of six species with different electrophoretic mobility in acrylamide gel electrophoresis. Three of these species were detected in Sephadex G-100 ovarian fraction OCA (from the void volume peak) and the other three species of lower apparent molecular weight were detected in fraction OCD (from the second peak). Fractions OCA and OCD did not share common antigenic determinations as determined by immunodiffusion. CEA was shown to share antigenic determinants with both OCA and OCD. A double-antibody radioimmunoassay capable of detecting nanogram quantities of plasma OCA was developed. In a preliminary study of ovarian cancer patients, OCA appeared to be a more sensitive marker for ovarian cancer than CEA. There was vitually no correlation (r2 - 0.1) between OCA and CEA levels in these patients, as determined by radioimmunoassay.
D000951:Antigens, Neoplasm / Q000032:analysis*; D001345:Autoradiography; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002850:Chromatography, Gel; D003429:Cross Reactions; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006801:Humans; D007122:Immunoelectrophoresis; D008970:Molecular Weight; D010051:Ovarian Neoplasms / Q000276:immunology*; D011247:Pregnancy; D011863:Radioimmunoassay
D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen